LONDON, May 13, 2020 – SIME Clinical AI, a pioneer in applying AI and data ingenuity to deliver rapid respiratory intensive care diagnostics, today announced that the U.S. Patent and Trademark Office has allowed US Patent Application No 14/893,822, further strengthening the Company’s intellectual property position in the lead-up to market entry. The patent was granted in Europe as EP 3004895 in 2019.
The coming US patent will provide valuable protection for the Company’s photonics and AI-based method for predicting neonatal respiratory distress syndrome in the first hour of life. Enabling doctors to deliver early and preventative treatment – improving clinical outcomes and reducing costs.
“This patent demonstrates our commitment to developing a next-generation diagnostic platform for the NICU,” said Povl Verder, Chief Executive Officer of SIME. “We are pleased with SIME’s development to date and excited about its potential to address this urgent and acute unmet need that affects millions of premature babies every year.”
